

Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA

NCT05181735

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Groupe Francophone des Myelodysplasies
Enrollment	150 participants

Key Eligibility Criteria

Inclusion (18)

- Patients must meet all of the following criteria to participate in the study:
 - Myelodysplastic syndrome according to current WHO classification
 - Age ≥ 18 years
 - Patients with lower risk MDS according to IPSS classification (LOW, INT-1) without RS who failed to achieved a response or who subsequently relapse after ESA (at least 60000 U EPO-a over at least 12weeks or equivalent), without disease progression (or ineligible to ESA defined by EPO > 500 U/I)
 - Hemoglobin < 9 gr/dl or Transfusion dependant (at least 3 RBCs in 16 wk in at least 2 transfusion episodes)
- ... and 13 more (see full listing online)

Exclusion (15)

- A patient meeting any of the following criteria is not eligible to participate in the study:
- Severe infection or any other uncontrolled severe condition.
- Uncontrolled hypertension
- Significant cardiac disease - NYHA Class III or IV or having suffered a myocardial infarction in the last 6 months.
- del(5q) syndrome

... and 10 more (see full listing online)

Locations (40 total)

CHU Amiens-Picardie, Amiens, France
Clinique de l'Europe, Amiens, France
CHU Angers, Angers, France
... and 37 more locations